A phase I/II study of dasatinib and dacarbazine in patients with metastatic melanoma.

Trial Profile

A phase I/II study of dasatinib and dacarbazine in patients with metastatic melanoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2012

At a glance

  • Drugs Dacarbazine; Dasatinib
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov
    • 25 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 May 2012 Planned end date changed from 1 Jul 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top